NUWE NUWELLIS INC

Nuwellis Appoints John Erb as Chief Executive Officer

Nuwellis Appoints John Erb as Chief Executive Officer

WHOWHATWHEREWHENHOW
John ErbAppointed as Chief Executive Officer



(no longer serving in an interim capacity)
Nuwellis HeadquartersEffective June 27, 2025Appointment confirmed by the Board of Directors following his interim leadership



MINNEAPOLIS, July 02, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to advancing solutions in fluid management, today announced the appointment of John Erb as its Chief Executive Officer. Erb, who has served as interim CEO since February 2025, will continue to lead the company with a focus on strategic clarity, operational discipline, and sustainable growth.

This marks Erb’s return to the CEO role at Nuwellis, having previously served in the position from 2015 – 2020. His reappointment reflects the Board’s confidence in his leadership and deep understanding of the company’s mission and potential. Under his interim leadership, Erb has brought stability and renewed momentum to the organization.

“I’m honored to lead Nuwellis at such a pivotal moment,” said John Erb, CEO of Nuwellis. “We have a passionate team, a therapy that saves lives, and a vision that resonates with clinicians. I’m excited to build on our strong foundation and drive the company forward.”

For more information about Nuwellis, please visit

About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn or Twitter.

About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.



For further information, please contact:

Investor Relations:
Rob Scott
Chief Financial Officer
 

Media Contact:
Leah McMullen
Director of Communications
 
EN
02/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summ...

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference Video webcast now available on-demand MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., today announced that of Nuwellis, participated in the . For the event, Mr. Erb dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s programs in development. The on-demand video webcast is now available on the as well as the  page under the  section of the Company’s website (). Abou...

 PRESS RELEASE

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Nuwellis Regains Compliance with Nasdaq Listing Requirements MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement under Listing Rule 5550(a)(2). On July 22, 2025, the Company received formal notice from Nasdaq stating that it has resolved the previously disclosed bid price deficiency. As a result, the hearing previously scheduled with the Nasdaq Hearings ...

 PRESS RELEASE

Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on Augu...

Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025 MINNEAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the second quarter 2025 on August 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website a...

 PRESS RELEASE

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus o...

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care WHOWHATWHENWHYNuwellis, Inc.Termination of theREVERSE-HF clinicaltrialJuly 17, 2025To redirect resources towardoutpatient markets where scalableimpact is highest.  MINNEAPOLIS, July 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. today announced the termination of its REVERSE-HF clinical trial, a randomized post-market trial evaluating ultrafiltration vs. IV loop diuretic therapy for fluid management in hospitalized heart failure patients. This decision reflects the compan...

 PRESS RELEASE

Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Lead...

Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation WHOWHATWHEREWHENWHYNuwellis, Inc.Issuance of U.S. Patent No. 12,357,734United States Patent and Trademark OfficeJuly 15, 2025To protect innovations in blood filtering system design and methods that support safe and precise fluid removal during ultrafiltration therapy. MINNEAPOLIS, July 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions, today announced the issuance by the U.S Patent and Trademark Offic...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch